Table 28 Antihypertensive activity of the synthesized compounds (70a-j) Goyal et al. [22]
From: Synthesis and therapeutic potential of imidazole containing compounds
Haemodynamic parameters | |||||
|---|---|---|---|---|---|
Compounds | SAP (mmHg) | DAP (mmHg) | MAP (mmHg) | HR (bpm) | |
70a | B | 189 ± 7 | 129 ± 5 | 159 ± 6 | 311 ± 19 |
A | 161 ± 9* | 105 ± 6* | 121 ± 5* | 298 ± 11 | |
70b | B | 189 ± 7 | 124 ± 8 | 154 ± 5 | 310 ± 18 |
A | 188 ± 6 | 122 ± 4 | 151 ± 7 | 320 ± 19 | |
70c | B | 206 ± 15 | 124 ± 8 | 151 ± 6 | 357 ± 15 |
A | 198 ± 18 | 119 ± 6 | 146 ± 5 | 337 ± 21 | |
70d | B | 217 ± 8 | 128 ± 6 | 160 ± 8 | 339 ± 17 |
A | 213 ± 7 | 132 ± 8 | 157 ± 9 | 330 ± 14 | |
70e | B | 221 ± 6 | 130 ± 5 | 157 ± 9 | 363 ± 16 |
A | 213 ± 3 | 129 ± 4 | 155 ± 8 | 347 ± 17 | |
70f | B | 178 ± 2 | 146 ± 7 | 151 ± 6 | 413 ± 28 |
A | 176 ± 3 | 144 ± 11 | 148 ± 9 | 402 ± 32 | |
70g | B | 194 ± 5 | 165 ± 8 | 180 ± 7 | 416 ± 18 |
A | 187 ± 7 | 155 ± 6 | 168 ± 6 | 409 ± 11 | |
70h | B | 158 ± 6 | 151 ± 9 | 155 ± 6 | 453 ± 29 |
A | 144 ± 5* | 141 ± 8* | 142 ± 9* | 459 ± 21 | |
70i | B | 198 ± 7 | 154 ± 7 | 176 ± 7 | 410 ± 19 |
A | 197 ± 6 | 148 ± 6 | 183 ± 8 | 406 ± 14 | |
70j | B | 140 ± 6 | 118 ± 7 | 127 ± 5 | 511 ± 45 |
A | 138 ± 5 | 115 ± 4 | 125 ± 4 | 465 ± 28 | |
Control | B | 169 ± 6 | 145 ± 3 | 154 ± 6 | 415 ± 23 |
A | 168 ± 9 | 140 ± 4 | 149 ± 7 | 407 ± 29 | |
Prazocin (3 mg/kg) | B | 199 ± 7 | 156 ± 6 | 168 ± 6 | 418 ± 17 |
A | 176 ± 8* | 138 ± 4* | 141 ± 3* | 411 ± 15 | |